Our majority-possessed subsidiary.

Arrowhead decreases second-one fourth consolidated operating expenses by 58 percent Arrowhead Research Corporation today announced financial results because of its fiscal 2010 second quarter ended March 31, 2010. In March, our majority-possessed subsidiary, Calando Pharmaceuticals, announced data that demonstrated initial proof of systemic delivery of gene and siRNA silencing via RNAi in humans nolvadex d tablets http://www.nolvadex-d.net . This is a thrilling milestone both for our Business and the broader sector. It had always been our goal to be the initial company to demonstrate systemic delivery, and we’ve achieved that goal today. Positive industry and marketplace reception has been encouraging and provides further validation and recognition of the potential value of this remarkable achievement.